Do BRAF inhibitors select for populations with different disease progression kinetics?

Paolo Antonio Ascierto, Ester Simeone, Antonio Maria Grimaldi, Marcello Curvietto, Assunta Esposito, Giuseppe Palmieri, Nicola Mozzillo

Research output: Contribution to journalArticlepeer-review


Ipilimumab, an anti-CTLA-4 monoclonal antibody, has been shown to improve overall survival in patients with metastatic melanoma. Preliminary data suggest that patients who fail BRAF inhibitor treatment experience a very rapid progression of disease. Such selectivity for more rapid disease progression may mean these patients do not receive the same benefit from subsequent treatment with ipilimumab as patients without prior BRAF inhibitor treatment. The current challenge is focused on how to identify and approach the two populations of fast and slow progressors and recent hypothesis suggest that treatment choice could be guided by baseline risk factors. However, no data have yet defined which the best sequence is and more research is needed to identify predictors of response in patients with metastatic melanoma to help guide whether a BRAF inhibitor or ipilimumab should be used first in sequential therapy.

Original languageEnglish
Article number61
JournalJournal of Translational Medicine
Issue number1
Publication statusPublished - Mar 8 2013

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)


Dive into the research topics of 'Do BRAF inhibitors select for populations with different disease progression kinetics?'. Together they form a unique fingerprint.

Cite this